Cross-Platform Omics Prediction procedure enables precision medicine in patients with stage-III melanoma

There is no consensus methodology that can account for the variation in omics signatures when they are acquired across different platforms and times. This poses a significant barrier to the implementation of valuable biomarkers into clinical practice. We present a novel procedure (Cross-Platform Omics Prediction) that accounts for these variations and demonstrates its utility in three risk models for different diseases that is suitable for prospective and multi-centre clinical implementation.